Investing in marketing to promote OTC erectile dysfunction treatment Eroxon across the Nordics has translated into sales growth for Navamedic.
Marketing Push For Eroxon Paying Off In Nordics
Navamedic is seeing good early sales for OTC ED treatment Eroxon in multiple Nordic markets after investing in a marketing push which includes a Mission Impossible-inspired commercial.
More from Earnings
• By
While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.
• By
The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.
• By
Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.
• By
Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.
More from Innovation & IP
• By
Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”
• By
Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.
• By
Advercheck managing director James Walmsley talks to HBW Insight about the challenges facing consumer health companies today as they move away from the prescription medicines sector and its pipeline of switchable ingredients towards self-care and prevention.